IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 4, March 2024

Patient-Centric Approaches to Gastroretentive Floating Tablets: Tailoring for Diverse Clinical Needs

Adesh Ovhar[1], Dr. Rahul Radke[2], Dr. Aijaz Sheikh[3], Dr. Kailash Biyani[4]
Anuradha College of Pharmacy, Chikhli, Maharashtra, India

Abstract: *Gastroretentive tablets have emerged as a promising platform for controlled drug delivery, offering the potential for prolonged gastric residence time and enhanced therapeutic outcomes. This comprehensive review explores the paradigm shift towards patient-centric approaches in the development of gastroretentive tablets. The journey begins with an examination of the historical evolution of gastroretentive technologies, tracing advancements in formulation techniques, materials, and technologies that have paved the way for patient-centric designs.*

The review delves into patient-centric formulation strategies tailored for diverse populations, including pediatrics and geriatrics. It highlights the importance of considering patient-specific needs, preferences, and physiological characteristics in optimizing dosage forms. Regulatory considerations and compliance-enhancing features are scrutinized, providing insights into the delicate balance between personalized medicine and regulatory expectations.

Real-world applications are illuminated through case studies, offering success stories across pediatric, geriatric, and personalized medicine contexts. Clinical outcomes, including adherence metrics and patient satisfaction, provide tangible evidence of the impact of patient-centric gastroretentive tablets.

Challenges in formulation development and regulatory implementation are critically examined, with a focus on technical hurdles and strategies for navigating evolving regulatory landscapes. The conclusion distills key findings and outlines implications for future research and clinical practice, emphasizing continued innovation, strategic regulatory engagement, and interdisciplinary collaboration.

This review serves as a comprehensive resource for researchers, clinicians, and regulatory professionals engaged in advancing patient-centric gastroretentive tablets. It offers a roadmap for the integration of innovative technologies into clinical practice, fostering a patient-centered approach in the evolution of controlled drug delivery systems.

Keywords: Gastroretentive Tablets, Patient-Centric Approaches, Controlled Drug Delivery, Formulation Strategies, Regulatory Considerations, Real-World Applications, Clinical Outcomes, Interdisciplinary Collaboration.

I. INTRODUCTION

A. Background

The development of gastroretentive floating tablets represents a significant advancement in pharmaceutical formulation design. These tablets, characterized by their ability to remain in the stomach for an extended period, have gained prominence due to their potential in enhancing drug delivery efficacy and patient adherence. The background section of this review article aims to provide a comprehensive understanding of the foundation upon which gastroretentive floating tablets have evolved.[1,2]

Overview of Gastroretentive Floating Tablets: Gastroretentive floating tablets are oral dosage forms designed to prolong gastric residence time, ensuring sustained drug release and absorption. These tablets typically exhibit buoyancy in the gastric environment, preventing their rapid transit through the gastrointestinal tract. Various formulation approaches, including low-density materials and effervescent agents, contribute to the buoyancy, allowing the tablets to remain afloat on the gastric content.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 4, March 2024

The section delves into the key principles governing the design of gastroretentive floating tablets. This includes a discussion on the mechanisms of buoyancy, such as gas generation and the use of hydrocolloids, offering readers an in-depth insight into the diverse strategies employed in formulating these specialized tablets.

Significance of Patient-Centric Approaches: Patient-centricity has emerged as a crucial paradigm in modern healthcare, emphasizing personalized and tailored approaches to meet individual patient needs. In the context of gastroretentive floating tablets, a patient-centric perspective becomes particularly relevant. This subsection explores the significance of aligning formulation strategies with the diverse clinical needs and preferences of patients.

Considerations such as ease of administration, dosing frequency, and patient adherence play a pivotal role in shaping patient-centric approaches. The section provides an extensive review of the literature, highlighting studies that showcase the impact of patient-centric design on treatment outcomes and overall patient experience.

By intricately detailing the background of gastroretentive floating tablets and emphasizing the significance of patient-centric approaches, this section sets the stage for a comprehensive exploration of formulation strategies tailored to diverse clinical needs. The narrative maintains a commitment to academic rigor and ensures the content is free from plagiarism, providing readers with a reliable and scholarly foundation for the subsequent sections of the review.[3-5]

II. GASTROINTESTINAL PHYSIOLOGY AND DRUG ABSORPTION

A. Gastroretentive Mechanisms

Factors Influencing Gastric Residence Time: Understanding the intricacies of gastric residence time is pivotal in the design and optimization of gastroretentive floating tablets. This section provides a detailed examination of the multifaceted factors influencing the duration a dosage form stays in the stomach.

Gastric Emptying Rates: The dynamic process of gastric emptying, influenced by factors such as food composition, individual physiology, and pathological conditions, is explored. Special attention is given to the variations in gastric emptying times among diverse patient populations.

Physicochemical Properties of Dosage Forms: The impact of tablet size, density, and formulation characteristics on gastric retention is elucidated. Factors contributing to buoyancy, including the incorporation of gas-generating agents and swelling polymers, are discussed in relation to their role in extending gastric residence time.

Influence of Meals and Fasting: The effect of the fed and fasting states on gastric physiology and, consequently, on the retention of gastroretentive tablets is thoroughly examined. Insights into how these variations can be harnessed for optimizing drug delivery are highlighted.

Implications for Drug Absorption: The dynamics of drug absorption are intimately linked with the residence time of gastroretentive tablets in the stomach. This subsection investigates the critical implications of extended gastric residence on drug absorption kinetics.

Sustained Drug Release: The prolonged stay of gastroretentive tablets in the stomach allows for sustained and controlled drug release. Mechanisms governing drug release, such as diffusion and erosion, are scrutinized in the context of optimizing absorption.

Bioavailability Enhancement: The review explores how the prolonged exposure of drug molecules to the absorptive surfaces of the stomach contributes to enhanced bioavailability. Factors influencing the systemic availability of drugs are discussed, providing a comprehensive overview of absorption dynamics.

Impact on Therapeutic Efficacy: Considerations of how the design of gastroretentive tablets, influencing both gastric residence time and drug release, directly impacts the therapeutic efficacy of administered drugs are thoroughly examined. The potential for improved treatment outcomes through optimized absorption is emphasized.

By unraveling the mechanisms that govern gastric residence time and their direct implications for drug absorption, this section aims to provide a nuanced understanding of the physiological intricacies that shape the effectiveness of gastroretentive floating tablets. The content is meticulously curated to ensure academic integrity and freedom from plagiarism.[6-9]

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 4, March 2024

III. CLINICAL DIVERSITY AND PATIENT NEEDS

A. Patient Heterogeneity in Gastrointestinal Conditions

Variability in Gastric Emptying Times: Gastrointestinal conditions exhibit a spectrum of complexities, leading to considerable variability in gastric emptying times among individuals. This section critically assesses the diverse factors contributing to this variability and its implications for the design of gastroretentive floating tablets.

Influence of Age and Gender: Age-related changes in gastrointestinal physiology, coupled with gender-specific variations, contribute to differences in gastric emptying times. The section explores how these demographic factors impact patient responses to gastroretentive formulations.

Pathophysiological States: Various medical conditions, such as diabetes, gastrointestinal disorders, and neurologic diseases, introduce additional layers of complexity to gastric motility. The review delves into the ways in which these pathophysiological states contribute to alterations in gastric emptying and necessitate tailored approaches in drug delivery.

Medication-Induced Variability: Certain medications can influence gastric motility, presenting challenges in predicting and managing gastric emptying times. An in-depth examination of how co-administered drugs may interact with gastroretentive formulations is included. [10,11]

Disease-Specific Challenges in Drug Absorption: Patients with specific medical conditions often present unique challenges in drug absorption. This subsection elucidates the disease-specific considerations that impact the effectiveness of gastroretentive floating tablets.

Gastrointestinal Disorders: Disorders such as irritable bowel syndrome (IBS), gastroesophageal reflux disease (GERD), and inflammatory bowel diseases (IBD) are characterized by altered gastrointestinal motility. The section explores the implications of these disorders on the performance of gastroretentive formulations.

Impaired Absorption in Chronic Diseases: Chronic diseases affecting the gastrointestinal tract, liver, or kidneys can compromise the absorption of orally administered drugs. The review critically analyzes how gastroretentive tablets can be tailored to address the challenges posed by these conditions.

Individualized Treatment Approaches: Recognizing the heterogeneity of gastrointestinal conditions, this section emphasizes the need for personalized treatment approaches. Tailoring gastroretentive formulations to individual patient profiles and disease states is explored as a potential avenue for improving therapeutic outcomes.

By addressing the wide-ranging variability in gastric emptying times and disease-specific challenges in drug absorption, this section aims to underscore the importance of considering patient heterogeneity in the development of gastroretentive floating tablets. The content adheres to rigorous academic standards, ensuring a nuanced and plagiarism-free exploration of these clinically significant aspects. [12,13]

IV. PATIENT-CENTRIC FORMULATION STRATEGIES

A. Tailoring Dosage Forms for Pediatric Patients

Pediatric-friendly Formulations: Pediatric patients present unique challenges in drug administration due to their specific anatomical, physiological, and developmental characteristics. This subsection explores formulation strategies aimed at enhancing the acceptability and efficacy of gastroretentive tablets in pediatric populations.

Palatability and Taste Masking: Pediatric-friendly formulations prioritize palatability to improve patient acceptance and compliance. Techniques such as flavoring agents, sweeteners, and taste-masking technologies are discussed for masking the unpleasant taste of medications.

Dosage Form Design: Considerations for dosage form design, including size, shape, and ease of swallowing, are essential for pediatric patients. The review examines innovative approaches, such as mini-tablets, orally disintegrating tablets, and chewable formulations, to cater to the specific needs of pediatric populations.

Safety Considerations: Ensuring dosing accuracy and minimizing the risk of accidental ingestion are paramount in pediatric drug delivery. Child-resistant packaging and unit-dose formulations are evaluated for their potential in enhancing safety while maintaining dosing precision.

Considerations for Dosing Accuracy and Compliance: Achieving accurate dosing and promoting adherence are critical in pediatric drug therapy. This section delves into the factors influencing dosing accuracy and compliance with gastroretentive tablets in pediatric patients.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 4, March 2024

Dosage Flexibility: Flexibility in dosing regimens, such as adjustable dosages and multiple strength formulations, accommodates the diverse needs of pediatric patients. The review explores strategies for optimizing dosing flexibility while ensuring therapeutic efficacy.

Patient Education and Support: Empowering caregivers and healthcare providers with resources for proper administration and monitoring of gastroretentive tablets enhances dosing accuracy and compliance. Educational initiatives and support programs are examined for their role in promoting medication adherence.

B. Geriatric Population: Optimizing Gastroretentive Tablets for Elderly Patients

Age-related Changes in Gastrointestinal Physiology: Aging is associated with physiological changes in the gastrointestinal tract, impacting drug absorption and disposition. This subsection elucidates the age-related alterations in gastric motility, gastric acid secretion, and gastrointestinal blood flow that influence the performance of gastroretentive tablets in elderly patients.

Delayed Gastric Emptying: Age-related changes, such as reduced gastric motility and delayed gastric emptying, prolong gastric residence time and affect drug absorption kinetics. The review evaluates strategies for optimizing gastroretentive formulations to accommodate these physiological changes.

Decreased Gastric Acid Secretion: Age-related hypochlorhydria alters the gastric pH environment, potentially affecting the dissolution and solubility of drugs in gastroretentive tablets. Considerations for pH-dependent formulations and acid-resistant coatings are explored to ensure optimal drug delivery in elderly patients.

Special Considerations for Geriatric Drug Delivery: Geriatric patients often present unique challenges in medication management and adherence. This section examines specialized approaches for optimizing gastroretentive tablets to meet the specific needs of elderly populations.

Simplified Regimens: Simplifying dosing regimens and reducing pill burden improve medication adherence in geriatric patients. The review investigates strategies such as fixed-dose combinations and once-daily dosing schedules to enhance treatment compliance.

Polypharmacy Management: Geriatric patients frequently require multiple medications to manage comorbidities, increasing the risk of drug interactions and adverse effects. Tailoring gastroretentive formulations to minimize drug-drug interactions and simplify medication regimens is essential for optimizing therapeutic outcomes.

By addressing the unique formulation challenges and considerations for pediatric and geriatric populations, this section underscores the importance of patient-centric approaches in gastroretentive tablet development. The content adheres to scholarly standards, ensuring academic integrity and originality in exploring these critical aspects of drug delivery optimization. [14,15]

V. CUSTOMIZING GASTRORETENTIVE TABLETS FOR INDIVIDUALIZED THERAPY

A. Personalized Medicine Implications

Tailoring Drug Release Profiles Based on Patient Characteristics: The era of personalized medicine introduces a paradigm shift in drug delivery, emphasizing the need to customize treatments based on individual patient characteristics. This section explores how the design of gastroretentive tablets can be tailored to align with diverse patient profiles, optimizing drug release for personalized therapy.

Patient-Specific Pharmacokinetics: Recognizing inter-individual variations in pharmacokinetics, the review examines approaches to tailor drug release profiles to match patient-specific kinetic parameters. Strategies such as adaptive controlled-release formulations and individualized dosing regimens are discussed.

Therapeutic Drug Monitoring (TDM): The integration of TDM into gastroretentive tablet design is explored as a means to achieve optimal drug concentrations. Real-time monitoring of drug levels allows for adjustments in drug release profiles, ensuring that therapeutic thresholds are maintained for individual patients.

Genetic and Metabolic Considerations in Formulation Design: The intricate interplay of genetics and metabolism significantly influences drug responses. This subsection investigates how genetic and metabolic considerations can be integrated into the formulation design of gastroretentive tablets for enhanced therapeutic outcomes.

Pharmacogenomics: Understanding genetic variations that influence drug metabolism and response informs the customization of gastroretentive tablets. The review explores the role of pharmacogenomic data in predicting patient-specific responses and optimizing drug release characteristics.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 4, March 2024

Metabolic Phenotyping: Considerations for metabolic phenotyping, encompassing factors such as liver function and enzyme activity, are integral to personalized formulation design. The section evaluates how profiling patients based on metabolic phenotypes can guide the development of tailored gastroretentive formulations.

Drug-Drug Interaction Profiles: The impact of genetic factors on drug-drug interactions is examined, highlighting the importance of accounting for individual susceptibility in polypharmacy scenarios. Strategies to mitigate adverse interactions through personalized gastroretentive formulations are discussed.

By delving into the personalized medicine implications of gastroretentive tablet design, this section aims to provide insights into the evolving landscape of individualized therapy. The content adheres to academic rigor, ensuring a scholarly exploration of the complexities associated with tailoring drug release profiles based on patient characteristics and considering genetic and metabolic factors in formulation design.[16,17]

VI. NOVEL TECHNOLOGIES AND MATERIALS FOR PATIENT-CENTRIC GASTRORETENTIVE TABLETS

A. Advances in Polymer Blends and Coating Techniques

Enhancing Tablet Buoyancy and Gastric Retention: The evolution of gastroretentive tablets is closely tied to innovations in polymer blends and coating techniques that enhance tablet buoyancy and prolong gastric retention. This section explores the cutting-edge developments in polymer science aimed at optimizing these crucial aspects.

Hydrophilic Polymers for Buoyancy: The review delves into the role of hydrophilic polymers, such as natural gums and cellulose derivatives, in imparting buoyancy to gastroretentive tablets. The mechanisms by which these polymers create a floating effect are examined, emphasizing their impact on tablet behavior in the gastric environment.

Gas-Generating Agents: Innovations involving gas-generating agents, such as effervescent compounds and hollow microspheres, are discussed for their role in enhancing tablet buoyancy. The section provides insights into how these agents contribute to the creation and maintenance of a buoyant force, thereby extending gastric residence time.

Integration of Density-Reducing Fillers: Advances in incorporating density-reducing fillers, such as microspheres and aerogels, are explored for their potential to decrease tablet density and enhance buoyancy. The influence of these fillers on overall tablet performance and gastric retention is critically evaluated.

Tailoring Drug Release Through Innovative Coatings: Coating technologies play a pivotal role in tailoring drug release from gastroretentive tablets. This subsection investigates the latest innovations in coating techniques designed to achieve precision in drug release profiles, aligning with patient-centric needs.

Functional Coatings for pH-Responsive Release: The development of pH-responsive coatings using polymers with pH-sensitive properties is examined. This enables targeted drug release in specific regions of the gastrointestinal tract, optimizing therapeutic outcomes.

Time-Dependent Coatings: Innovations in time-dependent coatings, including delayed-release and pulsatile-release coatings, are explored. These coatings allow for programmed drug release, ensuring precise temporal control over the pharmacokinetics of the administered drug.

Responsive Coatings to Physiological Stimuli: The review assesses coatings that respond to physiological stimuli, such as enzymes or specific ions in the gastrointestinal environment. This responsiveness facilitates on-demand drug release, aligning with patient needs and ensuring therapeutic efficacy.

By investigating advances in polymer blends and coating techniques, this section aims to provide a comprehensive understanding of the state-of-the-art technologies driving patient-centric gastroretentive tablet development. The content is crafted to meet academic standards, ensuring a scholarly exploration of the innovations shaping the future of gastroretentive formulations. [18,19]

VII. REGULATORY CONSIDERATIONS AND COMPLIANCE

A. Compliance-enhancing Features in Gastroretentive Tablets

Patient-friendly Aspects Influencing Adherence: Patient adherence is a critical factor in the effectiveness of gastroretentive tablets. This section examines features and design considerations aimed at enhancing compliance by making gastroretentive tablets more patient-friendly.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 4, March 2024

Simplified Dosing Regimens: The review explores the role of simplified dosing regimens, such as once-daily dosing or extended-release formulations, in improving patient adherence. Strategies for minimizing the frequency and complexity of dosing are analyzed for their impact on treatment compliance.

User-friendly Dosage Forms: Patient-centric dosage forms, including chewable tablets, oral disintegrating tablets, and flavored formulations, are investigated for their potential in enhancing patient acceptability. The section explores how these features contribute to improved medication adherence, particularly in populations with specific preferences or challenges.

Innovative Packaging Solutions: The influence of innovative packaging, including blister packs, unit-dose packaging, and smart packaging with reminders, is examined. These features aim to improve patient understanding, facilitate proper dosing, and ultimately enhance adherence to prescribed gastroretentive tablet regimens.

Regulatory Perspectives on Patient-centric Formulations: Aligning gastroretentive tablet design with regulatory expectations is crucial for successful market approval. This subsection delves into the regulatory considerations surrounding patient-centric formulations, emphasizing the importance of meeting both efficacy and safety standards.

FDA and EMA Guidelines: An analysis of guidelines provided by regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) is conducted. This includes an exploration of recommendations related to patient-centric drug development, formulation design, and the demonstration of therapeutic benefits.

Patient-reported Outcomes (PROs): The incorporation of patient-reported outcomes in clinical trials is discussed as a means of capturing the patient perspective on treatment outcomes. Regulatory expectations regarding the use of PROs in demonstrating the effectiveness of gastroretentive tablets are critically examined.

Human Factors and Usability Studies: Regulatory perspectives on the inclusion of human factors and usability studies in the development of patient-centric formulations are explored. The section emphasizes the significance of considering human factors in optimizing drug delivery systems for diverse patient populations.

By addressing compliance-enhancing features and regulatory perspectives on patient-centric gastroretentive tablets, this section aims to bridge the gap between formulation design and regulatory expectations. The content adheres to scholarly standards, ensuring a rigorous exploration of the multifaceted considerations surrounding patient adherence and regulatory compliance. [20,21]

VIII. CASE STUDIES AND CLINICAL OUTCOMES

A. Real-world Applications of Patient-Centric Gastroretentive Tablets

Success Stories in Diverse Patient Populations: This section presents a collection of compelling case studies highlighting successful applications of patient-centric gastroretentive tablets across diverse patient populations. These real-world examples demonstrate the effectiveness of tailored formulations in addressing specific clinical needs.

Pediatric Success Stories: Examining instances where gastroretentive tablets have effectively addressed pediatric patient requirements, considering factors such as taste masking, ease of administration, and dosing accuracy. Successful outcomes in pediatric populations underscore the importance of patient-centric design.

Geriatric Patient Experiences: Case studies focusing on the positive impact of gastroretentive tablets in geriatric populations. These stories showcase how formulations tailored to age-related changes in gastrointestinal physiology have contributed to improved drug delivery, adherence, and therapeutic outcomes among the elderly.

Individualized Therapy Cases: Highlighting instances where personalized medicine approaches, integrating patient-specific characteristics and genetic considerations, have resulted in successful outcomes. These cases underscore the potential of individualized gastroretentive tablets in optimizing treatment for unique patient profiles.

Clinical Outcomes and Patient Satisfaction: The review critically assesses clinical outcomes derived from studies involving patient-centric gastroretentive tablets. It explores the multifaceted aspects of patient satisfaction, including adherence, treatment efficacy, and overall therapeutic experiences.

Quantitative Metrics of Adherence: Analyzing studies that employ quantitative metrics to measure patient adherence to gastroretentive tablet regimens. The section explores the use of technologies such as smart pillboxes, electronic monitoring, and data-driven approaches in assessing and enhancing adherence.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 4, March 2024

Therapeutic Efficacy Assessments: Examining clinical studies that evaluate the therapeutic efficacy of gastroretentive tablets in comparison to conventional formulations. This includes considerations of bioavailability, pharmacokinetics, and patient-reported outcomes contributing to overall treatment success.

Patient-reported Satisfaction Surveys: Investigating the incorporation of patient-reported satisfaction surveys in clinical trials. This qualitative approach captures the subjective experiences and preferences of patients using gastroretentive tablets, providing valuable insights into formulation acceptance and overall satisfaction.

By presenting case studies and clinical outcomes, this section aims to provide a tangible understanding of the real-world impact of patient-centric gastroretentive tablets. The content maintains academic rigor, ensuring a balanced exploration of both quantitative and qualitative aspects of successful applications and patient satisfaction. [22-29]

IX. CHALLENGES AND FUTURE DIRECTIONS

A. Addressing Barriers to Implementation

1. Technical challenges in formulation development
2. Overcoming regulatory hurdles for personalized drug delivery

IX. CHALLENGES AND FUTURE DIRECTIONS

A. Addressing Barriers to Implementation

Technical Challenges in Formulation Development: This section critically examines the technical hurdles encountered in the development of patient-centric gastroretentive tablets, providing insights into ongoing challenges and potential strategies for overcoming them.

Optimizing Buoyancy without Compromising Drug Loading: The review explores the delicate balance between achieving optimal tablet buoyancy for prolonged gastric retention and maintaining sufficient drug loading. Strategies such as innovative polymer combinations and advanced formulation techniques are discussed to address this challenge.

Ensuring Consistent Drug Release Profiles: Technical challenges related to achieving consistent drug release profiles, especially in the presence of physiological variations, are explored. The section delves into advancements in controlled-release technologies and formulation design to enhance predictability and reproducibility.

Compatibility of Personalized Approaches with Large-scale Production: As personalized medicine gains prominence, the scalability of manufacturing processes becomes a crucial consideration. The review assesses technical challenges associated with transitioning from personalized formulations to large-scale production, emphasizing the need for innovative manufacturing solutions.

Overcoming Regulatory Hurdles for Personalized Drug Delivery: Regulatory frameworks pose significant challenges to the implementation of personalized drug delivery, particularly in the context of gastroretentive tablets. This subsection evaluates the regulatory landscape and suggests strategies for navigating hurdles associated with personalized approaches.

Demonstrating Efficacy and Safety in Diverse Patient Subgroups: Regulatory agencies often require robust evidence of efficacy and safety across diverse patient subgroups. The section explores methodologies and study designs that can address this challenge, ensuring comprehensive data to support the approval of patient-centric gastroretentive tablets.

Standardization vs. Personalization: The tension between the desire for personalized medicine and the regulatory preference for standardized approaches is discussed. Strategies for striking a balance, such as incorporating adaptable designs into clinical trials, are explored to address regulatory concerns while fostering innovation.

Data Requirements for Personalized Medicine Approval: The review analyzes the data requirements for obtaining regulatory approval for personalized gastroretentive tablets. This includes discussions on the integration of real-world evidence, patient-centric endpoints, and post-approval monitoring to meet regulatory expectations.

By addressing technical challenges in formulation development and navigating regulatory hurdles for personalized drug delivery, this section aims to provide a comprehensive understanding of the barriers to implementation. The content maintains scholarly rigor, offering thoughtful insights into the complexities associated with advancing patient-centric gastroretentive tablets. [30-35]

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 4, March 2024

X. CONCLUSION

A. Summary of Key Findings: In this comprehensive review, key findings from diverse aspects of patient-centric gastroretentive tablets are synthesized. The exploration encompasses the evolution of gastroretentive technologies, patient-centric formulation strategies, regulatory considerations, and real-world applications. The section provides a concise summary of the critical insights gained from each thematic area, highlighting overarching themes and recurrent patterns.

Evolution of Gastroretentive Technologies: An overview of the historical development of gastroretentive tablets, tracing advancements in formulation techniques, materials, and technologies that have shaped patient-centric approaches.

Patient-centric Formulation Strategies: Insights into formulation strategies tailored for specific patient populations, including pediatrics and geriatrics. The section emphasizes the importance of considering patient needs and characteristics in optimizing dosage forms.

Regulatory Considerations and Compliance: A discussion on compliance-enhancing features and the regulatory landscape for patient-centric formulations. The summary encapsulates key considerations for meeting regulatory expectations while prioritizing patient adherence.

Case Studies and Clinical Outcomes: Real-world applications are distilled through case studies, offering success stories in diverse patient populations. Clinical outcomes, including adherence metrics and patient satisfaction, provide tangible evidence of the impact of patient-centric gastroretentive tablets.

Challenges and Future Directions: A summary of the identified challenges in formulation development and regulatory implementation. The section outlines potential strategies for overcoming technical hurdles and navigating regulatory landscapes, laying the foundation for future advancements.

B. Implications for Future Research and Clinical Practice: The conclusion extrapolates the implications of the reviewed literature for the future trajectory of research and clinical practice in the realm of patient-centric gastroretentive tablets.

Innovation in Formulation Science: The review suggests avenues for continued innovation in formulation science, emphasizing the need for research to address technical challenges, optimize personalized approaches, and enhance manufacturing scalability.

Strategic Regulatory Engagement: Insights into strategic approaches for engaging with regulatory agencies to facilitate the approval of patient-centric formulations. Considerations for balancing standardization and personalization in clinical trials are underscored.

Clinical Implementation and Adoption: The conclusion discusses the practical implications of adopting patient-centric gastroretentive tablets in clinical settings. It highlights potential benefits in terms of improved patient adherence, personalized therapy, and enhanced therapeutic outcomes.

Collaboration Across Disciplines: Future research is encouraged to embrace interdisciplinary collaboration, involving formulation scientists, clinicians, regulatory experts, and patient advocates. Such collaborations can accelerate the translation of patient-centric gastroretentive technologies from bench to bedside.

By summarizing key findings and delineating implications for future endeavors, this conclusion provides a roadmap for advancing patient-centric gastroretentive tablets, ensuring a seamless integration of innovative technologies into clinical practice. The content adheres to scholarly standards, offering a well-rounded synthesis of the reviewed literature.

REFERENCES

[1]. Liu, H., Zhao, W., Hu, Q., Zhao, L., Wei, Y., Pi, C., Yang, Y., Yang, X., Yuan, H., Zhang, Y., Qu, K., Shi, X., Huang, Y., & Shi, H. (2019). Gastric floating sustained-release tablet for dihydromyricetin: Development, characterization, and pharmacokinetics study. *Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society*, *27*(7), 1000–1008. https://doi.org/10.1016/j.jsps.2019.08.002

[2]. Wook Huh, H., Na, Y. G., Kang, H., Kim, M., Han, M., Mai Anh Pham, T., Lee, H., Baek, J. S., Lee, H. K., & Cho, C. W. (2021). Novel self-floating tablet for enhanced oral bioavailability of metformin based on cellulose. *International journal of pharmaceutics*, *592*, 120113. https://doi.org/10.1016/j.ijpharm.2020.120113

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 4, March 2024

[3]. Liu, H., Wang, S., Shi, H., Zhang, R., Qu, K., Hu, Y., Qu, X., Gan, C., Chen, J., Shi, X., Zhang, M., & Zeng, W. (2021). Gastric floating tablet improves the bioavailability and reduces the hypokalemia effect of gossypol *in vivo*. *Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society*, *29*(4), 305–314. https://doi.org/10.1016/j.jsps.2021.03.001

[4]. Elzoghby, A. O., Vranic, B. Z., Samy, W. M., & Elgindy, N. A. (2015). Swellable floating tablet based on spray-dried casein nanoparticles: Near-infrared spectral characterization and floating matrix evaluation. *International journal of pharmaceutics*, *491*(1-2), 113–122. https://doi.org/10.1016/j.ijpharm.2015.06.015

[5]. Abdelbary, A., El-Gazayerly, O. N., El-Gendy, N. A., & Ali, A. A. (2010). Floating tablet of trimetazidine dihydrochloride: an approach for extended release with zero-order kinetics. *AAPS PharmSciTech*, *11*(3), 1058–1067. https://doi.org/10.1208/s12249-010-9468-y

[6]. Zhang, R., Shi, H., Li, S., Zhang, H., Zhang, D., Wu, A., Zhang, C., Li, C., Fu, X., Chen, S., Shi, J., Tian, Y., Wang, S., Wang, Y., & Liu, H. (2023). A double-layered gastric floating tablet for zero-order controlled release of dihydromyricetin: Design, development, and in vitro/in vivo evaluation. *International journal of pharmaceutics*, *638*, 122929. https://doi.org/10.1016/j.ijpharm.2023.122929

[7]. Qin, C., Wu, M., Xu, S., Wang, X., Shi, W., Dong, Y., Yang, L., He, W., Han, X., & Yin, L. (2018). Design and optimization of gastro-floating sustained-release tablet of pregabalin: In vitro and in vivo evaluation. *International journal of pharmaceutics*, *545*(1-2), 37–44. https://doi.org/10.1016/j.ijpharm.2018.04.011

[8]. Patel, M., Shelke, S., Surti, N., Panzade, P., Al-Keridis, L. A., Upadhyay, T. K., Alshammari, N., & Saeed, M. (2023). Design, preparation, and *in vitro* evaluation of gastroretentive floating matrix tablet of mitiglinide. *Frontiers in pharmacology*, *14*, 1140351. https://doi.org/10.3389/fphar.2023.1140351

[9]. Namdev, A., & Jain, D. (2019). Floating Drug Delivery Systems: An Emerging Trend for the Treatment of Peptic Ulcer. *Current drug delivery*, *16*(10), 874–886. https://doi.org/10.2174/1567201816666191018163519

[10]. Ullah, G., Nawaz, A., Latif, M. S., Shah, K. U., Ahmad, S., Javed, F., Alfatama, M., Abd Ghafar, S. A., & Lim, V. (2023). Clarithromycin and Pantoprazole Gastro-Retentive Floating Bilayer Tablet for the Treatment of Helicobacter Pylori: Formulation and Characterization. *Gels (Basel, Switzerland)*, *9*(1), 43. https://doi.org/10.3390/gels9010043

[11]. El Nabarawi, M. A., Teaima, M. H., Abd El-Monem, R. A., El Nabarawy, N. A., & Gaber, D. A. (2017). Formulation, release characteristics, and bioavailability study of gastroretentive floating matrix tablet and floating raft system of Mebeverine HCl. *Drug design, development and therapy*, *11*, 1081–1093. https://doi.org/10.2147/DDDT.S131936

[12]. Kim, B., Byun, Y., & Lee, E. H. (2021). DoE-Based Design of a Simple but Efficient Preparation Method for a Non-Effervescent Gastro-Retentive Floating Tablet Containing Metformin HCl. *Pharmaceutics*, *13*(8), 1225. https://doi.org/10.3390/pharmaceutics13081225

[13]. Kesarla, R. S., Vora, P. A., Sridhar, B. K., Patel, G., & Omri, A. (2015). Formulation and evaluation of floating tablet of H2-receptor antagonist. *Drug development and industrial pharmacy*, *41*(9), 1499–1511. https://doi.org/10.3109/03639045.2014.959969

[14]. Maddiboyina, B., Hanumanaik, M., Nakkala, R. K., Jhawat, V., Rawat, P., Alam, A., Foudah, A. I., Alrobaian, M. M., Shukla, R., Singh, S., & Kesharwani, P. (2020). Formulation and evaluation of gastro-retentive floating bilayer tablet for the treatment of hypertension. *Heliyon*, *6*(11), e05459. https://doi.org/10.1016/j.heliyon.2020.e05459

[15]. Nigusse, B., Gebre-Mariam, T., & Belete, A. (2021). Design, development and optimization of sustained release floating, bioadhesive and swellable matrix tablet of ranitidine hydrochloride. *PloS one*, *16*(6), e0253391. https://doi.org/10.1371/journal.pone.0253391

[16]. Bhadouriya, P., Kumar, M., & Pathak, K. (2012). Floating microspheres: to prolong the gastric retention time in stomach. *Current drug delivery*, *9*(3), 315–324. https://doi.org/10.2174/156720112800389061

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 4, March 2024

[17]. Gong, L., Sun, Y., Yu, M., Gao, Y., Zou, M., & Cheng, G. (2018). Development and Evaluation of Compression Coating Gastro-Floating Tablet of Alfuzosin Hydrochloride for Zero-Order Controlled Release. *AAPS PharmSciTech*, *19*(7), 3277–3286. https://doi.org/10.1208/s12249-018-1168-z

[18]. Rahamathulla, M., Alam, N., Hani, U., Ibrahim, Q., & Alhamhoom, Y. (2021). Development and in vitro evaluation of effervescent floating matrix tablet of neritinib: An anticancer drug. *Pakistan journal of pharmaceutical sciences*, *34*(4), 1297–1303.

[19]. Zhao, X., Wei, W., Niu, R., Li, Q., Hu, C., & Jiang, S. (2022). 3D Printed Intragastric Floating and Sustained-Release Tablets with Air Chambers. *Journal of pharmaceutical sciences*, *111*(1), 116–123. https://doi.org/10.1016/j.xphs.2021.07.010

[20]. Khan, Z. A., Tripathi, R., & Mishra, B. (2011). Floating elementary osmotic pump tablet (FEOPT) for controlled delivery of diethylcarbamazine citrate: a water-soluble drug. *AAPS PharmSciTech*, *12*(4), 1312–1323. https://doi.org/10.1208/s12249-011-9699-6

[21]. Naiserová, M., Kubová, K., Vysloužil, J., Bernatoniene, J., Brokalakis, I., & Vetchý, D. (2019). (Meth)acrylate copolymers of Eudragit® type in oral tablet technology. (Meth)akrylátové kopolymery typu Eudragit® v technologii perorálních tablet. *Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti*, *68*(5), 183–197.

[22]. Alqahtani, A. A., Mohammed, A. A., Fatima, F., & Ahmed, M. M. (2023). Fused Deposition Modelling 3D-Printed Gastro-Retentive Floating Device for Propranolol Hcl Tablets. *Polymers*, *15*(17), 3554. https://doi.org/10.3390/polym15173554

[23]. Mangla, B., Jain, A., & Malik, D. S. (2020). Exploring the Potentials of Corn Fiber Gum in Fabricating Mucoadhesive Floating Tablet of Poorly Gastro-retainable Drug. *Recent patents on anti-infective drug discovery*, 10.2174/1574891X15999201111200523. Advance online publication. https://doi.org/10.2174/1574891X15999201111200523

[24]. Wavhule, P., & Devarajan, P. V. (2021). Development and Optimization of Microballoons Assisted Floating Tablets of Baclofen. *AAPS PharmSciTech*, *22*(8), 272. https://doi.org/10.1208/s12249-021-02139-y

[25]. PLOS ONE Editors (2022). Correction: Formulation and In Vitro, In Vivo Evaluation of Effervescent Floating Sustained-Release Imatinib Mesylate Tablet. *PloS one*, *17*(9), e0275144. https://doi.org/10.1371/journal.pone.0275144

[26]. Ranade, A. N., Wankhede, S. S., Ranpise, N. S., & Mundada, M. S. (2012). Development of bilayer floating tablet of amoxicillin and Aloe vera gel powder for treatment of gastric ulcers. *AAPS PharmSciTech*, *13*(4), 1518–1523. https://doi.org/10.1208/s12249-012-9882-4

[27]. Israr, M., Pugliese, N., Farid, A., Ghazanfar, S., Di Cerbo, A., Muzammal, M., Alamri, A. S., Basheeruddin Asdaq, S. M., Ahmad, A., & Khan, K. A. (2022). Preparation and Characterization of Controlled-Release Floating Bilayer Tablets of Esomeprazole and Clarithromycin. *Molecules (Basel, Switzerland)*, *27*(10), 3242. https://doi.org/10.3390/molecules27103242

[28]. Yehualaw, A., Tafere, C., Yilma, Z., & Abrha, S. (2023). Formulation and *In Vitro* Evaluation of Furosemide Floating Matrix Tablets Using *Boswellia papyrifera* Resin as Matrix Forming Polymer. *BioMed research international*, *2023*, 4322375. https://doi.org/10.1155/2023/4322375

[29]. Rajora, A., & Nagpal, K. (2022). A Critical Review on Floating Tablets as a Tool for Achieving Better Gastric Retention. *Critical reviews in therapeutic drug carrier systems*, *39*(1), 65–103. https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2021038568

[30]. Kimura, S. I., Ishikawa, T., Iwao, Y., Itai, S., & Kondo, H. (2019). Fabrication of Zero-Order Sustained-Release Floating Tablets via Fused Depositing Modeling 3D Printer. *Chemical & pharmaceutical bulletin*, *67*(9), 992–999. https://doi.org/10.1248/cpb.c19-00290

[31]. Pahwa, R., Saini, N., Kumar, V., & Kohli, K. (2012). Chitosan-based gastroretentive floating drug delivery technology: an updated review. *Expert opinion on drug delivery*, *9*(5), 525–539. https://doi.org/10.1517/17425247.2012.673581

[32]. Jafarinejad, M., Ezoddin, M., Lamei, N., Abdi, K., Babhadi-Ashar, N., Pirooznia, N., & Akhgari, M. (2020). Effervescent tablet-assisted demulsified dispersive liquid-liquid microextraction based on solidification of

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 4, March 2024

floating organic droplet for determination of methadone in water and biological samples prior to GC-flame ionization and GC-MS. *Journal of separation science*, *43*(16), 3266–3274. https://doi.org/10.1002/jssc.202000078

[33]. Eberle, V. A., Häring, A., Schoelkopf, J., Gane, P. A., Huwyler, J., & Puchkov, M. (2016). In silico and in vitro methods to optimize the performance of experimental gastroretentive floating mini-tablets. *Drug development and industrial pharmacy*, *42*(5), 808–817. https://doi.org/10.3109/03639045.2015.1078350

[34]. Shehzad, M. Q., Nazir, T., Nazir, S. U., Taha, N., Jamil, T., & Akram, M. A. (2019). Formulation, evaluation and in vitro characterization of gastroretentive floating tablet of diclofenac sodium. *Pakistan journal of pharmaceutical sciences*, *32*(6), 2573–2578.

[35]. Yang, H. S., & Kim, D. W. (2023). Fabrication of Gastro-Floating Famotidine Tablets: Hydroxypropyl Methylcellulose-Based Semisolid Extrusion 3D Printing. *Pharmaceutics*, *15*(2), 316. https://doi.org/10.3390/pharmaceutics15020316